Redeye raises its base case following solid progress in Nanexa's pipeline and a clearer view of the financial situation following the outcome of the warrant program and first investment from Applied Ventures. In our view, 2021 will be a pivotal year for Nanexa - with the readout from the phase I study of NEX-18 as the most important trigger.